A Targeted Therapy Combination for Solid Tumors
The FDA approved a combination of two kinase inhibitors for the treatment of solid tumors bearing the BRAF V600E...
Progress Against Cancer
The FDA approved a combination of two kinase inhibitors for the treatment of solid tumors bearing the BRAF V600E...
The FDA has approved an immunotherapy to be used in combination with another immunotherapy or chemotherapy for the treatment...
The FDA granted accelerated approval to a CAR T-cell therapy for certain adult patients with follicular lymphoma. The U.S....
The FDA approved a new regimen that includes a molecularly targeted therapeutic for some older leukemia patients not eligible...
The FDA approved the chemotherapeutic azacitidine for patients with juvenile myelomonocytic leukemia The U.S. Food and Drug Administration (FDA)...
The FDA has granted full approval to an antibody-drug conjugate for certain patients with breast cancer. The U.S. Food...
The FDA approved the cellular immunotherapy axicabtagene ciloleucel for second-line treatment of patients with large B-cell lymphoma. The U.S....
The FDA has approved a radioactive compound and companion diagnostic test for patients with advanced prostate cancer. The U.S....
The FDA approved pembrolizumab for certain patients with advanced endometrial cancer with DNA repair defects The U.S. Food and...
The FDA approved nivolumab and relatlimab-rmbw (Opdualag) for some patients with advanced melanoma The U.S. Food and Drug...